PULM (Pulmatrix Corp) מכפיל מחיר להכנסות עתידי
The modeled P/S of Pulmatrix, Inc. (PULM) demonstrates market expectations, where the value of 46.50 reflects this status. This trend is based on the implementation of laboratory automation for molecular analysis. Prospects depend on the efficiency of lung drug delivery via iSPERSE. Growth is driven by PUR1900 trials and the search for partners for cystic fibrosis therapy, which determines the investment attractiveness of this biotech.
פילוחי מדדים ואנליטיקה של חברת Pulmatrix Corporation (PULM)
The robotization of precision powder engineering at Pulmatrix, Inc. (PULM) minimizes manual labor, creating a foundation for revenue scaling. The ratio of market capitalization to projected sales allows for a valuation of this technological advantage, preventing overpayment based on unjustified optimism. By analyzing the forward P/S multiple, an investor can identify arbitrage gaps and acquire shares at a discount during maximum price drawdowns relative to expected growth.
